#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

CANVAS – canagliflozin and cardiovascular or renal influence for diabetes mellitus type 2


Authors: Vítovec J. 1;  Špinar J. 2;  Špinarová L. 1
Authors‘ workplace: I. interní kardioangiologická klinika LF MU a FN u sv. Anny v Brně 1;  Lékařská fakulta MU Brno 2
Published in: Kardiol Rev Int Med 2019, 21(1): 15-18

Overview

Canagliflozin is a sodium-glucose cotransporter 2 inhibitor that reduces glycaemia as well as blood pressure, body weight, and albuminuria in people with diabetes. The CANVAS Programme integrated data from two trials involving a total of 10,142 participants with type 2 diabetes and high cardiovascular risk. Participants in each trial were randomly assigned to receive canagliflozin or placebo and were followed for a mean of 188.2 weeks. The primary outcome was a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. Conclusions: In two trials involving patients with type 2 diabetes and an elevated risk of cardiovascular disease, patients treated with canagliflozin had a significantly lower risk of cardiovascular events than those who received placebo. A boundary higher risk of amputation, primarily at the level of the toe or metatarsus was observed in the study. These complications, however, were not proved in subsequent observational databases.

Keywords:

cardiovascular and renal safety – type 2 diabetes mellitus – canagliflozin – programme CANVAS


Sources

1. Nies­sner A, Tamargo J, Kol­ler L et al. Non-insulin antidiabetic pharmacother­apy in patients with established cardiovascular dis­ease: a position paper of the ESC Work­­ing Group on Cardiovascular Pharmacother­apy. Eur Heart J 2018; 39(24): 2274–2281. doi: 10.1093/eurheartj/ehx625.

2. Neal B, Perkovic V, Mahaf­fey KW et al. CANVAS Program Col­laborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017; 377(7): 644–657. doi: 10.1056/NEJMoa1611925.

3. Rådholm K, Figtree G, Perkovic V et al. Canagliflozin and heart failure in type 2 diabetes mel­litus. Results From the CANVAS Prog­ram. Circulation 2018; 138(5): 458–468. doi: 10.1161/CIRCULATIONAHA.118.034222.

4. Edelsberger T. Glukuretika (inhibitory SGLT2, glifloziny) v léčbě diabetu. Remedia 2011; 21: 46–53.

5. Heerspink HJ, Perkins BA, Fitchett DH et al. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mel­litus: cardiovascular and kidney ef­fects, potential mechanisms, and clinical applications. Circulation 2016; 134(10): 752–772. doi: 10.1161/CIRCULATIONAHA.116.021887.

6. Wild­­ing JP, Woo V, Soler NG et al. Sustained ef­fectiveness of dapagliflozin over 48 weeks in patients with type 2 diabetes poorly control­led with insulin. Diabetes 2010; 59 (Suppl. 1): Abstract 0021–LB.

7. Adamíková A. Kanagliflozin – místo v léčbě diabetes mel­litus 2. typu. Farmakoterapeutická Revue 2018; 1: 8–13.

8. SPC Invokana. Dostupné na: http://www.sukl.cz/modules/medication/detail.php?code=0194605&tab=prices.

9. Yuan Z, DeFalco FJ, Ryan PB et al. Risk of lower extremity amputations in people with type 2 diabetes mel­litus treated with sodium-glucose co-transporter-2 inhibitors in the USA: A retrospective cohort study. Diabetes Obes Metab 2018; 20(3): 582–589. doi: 10.1111/dom.13115.

10. Ryan PB, Buse JB, Schuemie MJ et al. Comparative ef­fectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mel­litus: A real-world meta-analysis of 4 observational databases (OBSERVE-4D). Diabetes Obes Metab 2018; 20(11): 2585–2597. doi: 10.1111/dom.13424.

11. Bode B, Stenlöf K, Har­ris S. Long-term ef­ficacy and safety of CANA over 104 weeks in patients aged 55 to 80 years with type 2 diabetes. Diabetes Obes Metab 2015; 17(3): 294–303. doi: 10.1111/dom.12428.

12. Jardine MJ, Mahaf­fey KW, Neal B et al. The canagliflozin and renal endpoints in diabetes with established nephropathy clinical evaluation (CREDENCE) study rationale, design and baseline characteristics. Am J Nephrol 2017; 46(6): 462–472. doi: 10.1159/000484633.

13. Palmer C. CREDENCE canagliflozin trial halted because of efficacy. Cardiology News 2018. Avail­able at: https://www.mdedge.com/cardiology/article/170423/diabetes/credence-canagliflozin-trial-halted-because-efficacy.

Labels
Paediatric cardiology Internal medicine Cardiac surgery Cardiology
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#